# US 2016/0256538 A1 · Use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256538 A1
- Document ID: US20160256538A1
- Status: Published application
- Kind: A1
- Application number: 14/877,601
- Filed: 2015-10-07
- Published: 2016-09-08
- Earliest claimed: 2010-10-01
- Assignees: The Trustees of the University of Pennsylvania; University of Georgia Research Foundation, Inc.
- Applicants: The Trustees of the University of Pennsylvania; University of Georgia Research Foundation, Inc.
- Inventors: Donald A. HARN, JR.; Yvonne Paterson; Lisa McEwen
- Web page: https://patentgrep.com/patent/US20160256538A1

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0003: {Invertebrate antigens}
- A61K 39/12: Viral antigens
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/06: Antimalarials
- A61P 33/10: Anthelmintics
- A61P 33/12: Schistosomicides
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 2039/523: {expressing foreign proteins}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/577: {tolerising response}
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention relates to methods of using a Listeria vaccine vector to induce a Th1 immune response in subjects having persistent Th2 immune response profiles.

## Claims

### Claim 1

A method of treating an infectious disease in a subject having a Th2 phenotypic profile, the method comprising the step of administering to said subject a therapeutically effective dose of a Listeria vaccine vector, wherein said Listeria vaccine vector expresses and secretes an antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, wherein said antigen is an infectious disease antigen, and wherein said administering produces a Th1 cell-mediated immune response in said subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said Th2 phenotypic profile is parasite-induced.

### Claim 3 (depends on 2)

The method of claim 2, wherein said parasite is a helminth, or a protozoan parasite.

### Claim 4 (depends on 3)

The method of claim 3, wherein said helminth is Schistosoma mansoni.

### Claim 5 (depends on 3)

The method of claim 3, wherein said protozoan parasite is malaria, leishmania, toxoplasma.

### Claim 6 (depends on 1)

The method of claim 1, wherein said additional polypeptide is a non-hemolytic Listeriolysin O (LLO) polypeptide, an ActA polypeptide, or a PEST sequence.

### Claim 7 (depends on 1)

The method of claim 1, wherein said subject is human.

### Claim 8 (depends on 1)

The method of claim 1, wherein said antigen is an HIV antigen, a malaria antigen, or a tuberculosis antigen.

### Claim 9 (depends on 8)

The method of claim 8, wherein said antigen elicits an immune response to HIV-1 gag cytotoxic T lymphocyte or to HIV-1 gag T helper epitopes.

### Claim 10 (depends on 8)

The method of claim 8, wherein said HIV antigen is HIV-gag, pol, env, protease, rev, tat, nef, vif, or vpr.

### Claim 11 (depends on 8)

The method of claim 8, wherein said malaria antigen is circumsprozoite protein (CSP), sporozoite surface protein 2 (PfSSP), liver stage antigen 1 (LSA1), merozoite surface protein 1 (MSP-1), serine repeat antigen and AMA-1, Pfs25, schizont export protein, 19 repeats of the sprozoite surface protein (NANP), SPf66, recombinant (Asn-Ala-Pro15Asn-Val-Asp-Pro)2-Leu-Arg(R32LR) protein covalently bound to a purified Pseudomonas aeruginosa toxin, NYVAC-Pf7, (NANP)19-5.1, (RTS,S, RTS,S/AS01), or a combination thereof.

### Claim 12 (depends on 8)

The method of claim 8, wherein said tuberculosis antigen is ESAT-6, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64, MPT64, Ag85A, Ag85B (MPT59), Mtb39, MPB59, Ag85C, 19 kDa lipoprotein, MPT32 and alpha-crystallin, EsxG, Rv2430c, Rv2041c, or at least on T-cell epitope of any of the above.

### Claim 13 (depends on 1)

The method of claim 1, further comprising the step of administering a booster vaccination.

### Claim 14 (depends on 13)

The method of claim 13, wherein said booster vaccination comprises a DNA vaccine encoding said antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, a recombinant polypeptide comprising said antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, a viral vector encoding said antigen fused to an additional immunogenic polypeptide or a signal sequence thereof or a live recombinant Listeria vaccine vector.

### Claim 15 (depends on 1)

The method of claim 1, wherein said Th1 immune response is a cytotoxic T-cell response or a memory T-cell response.

### Claim 16 (depends on 1)

The method of claim 1, wherein said Listeria vaccine vector is a recombinant auxotrophic dal/dat mutant Listeria strain.

### Claim 17 (depends on 1)

The method of claim 1, wherein said Listeria vaccine vector comprises an actA gene mutation.

### Claim 18 (depends on 1)

The method of claim 1, wherein said Listeria vaccine vector comprises an inlB gene mutation.

### Claim 19 (depends on 1)

The method of claim 1, wherein said Listeria vaccine vector comprises an actA and inlB gene mutation.

### Claim 20 (depends on 1)

The method of claim 1, wherein said immune response is against an infectious disease in said subject.

### Claim 21 (depends on 1)

The method of claim 1, wherein said infectious disease is amebiasis, an HIV infection, a malaria infection, a leishmania infection, a trichuris infection, or a tuberculosis infection.

### Claim 22

A method of preventing an infectious disease in a subject having a Th2 phenotypic profile, the method comprising the step of administering to said subject a therapeutically effective dose of a Listeria vaccine vector, wherein said Listeria vaccine vector expresses and secretes an antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, wherein said antigen is an infectious disease antigen, and wherein said administering produces a Th1 cell-mediated immune response in said subject.

### Claim 23 (depends on 22)

The method of claim 22, wherein said Th2 phenotypic profile is parasite-induced.

### Claim 24 (depends on 23)

The method of claim 23, wherein said parasite is a helminth, or a protozoan parasite.

### Claim 25 (depends on 24)

The method of claim 24, wherein said helminth is Schistosoma mansoni.

### Claim 26 (depends on 24)

The method of claim 24, wherein said protozoan parasite is malaria, leishmania, toxoplasma.

### Claim 27 (depends on 22)

The method of claim 22, wherein said additional polypeptide is a non-hemolytic Listeriolysin O (LLO) polypeptide, an ActA polypeptide, or a PEST sequence.

### Claim 28 (depends on 22)

The method of claim 22, wherein said subject is human.

### Claim 29 (depends on 22)

The method of claim 22, wherein said antigen is an HIV antigen, a malaria antigen, or a tuberculosis antigen.

### Claim 30 (depends on 29)

The method of claim 29, wherein said antigen elicits an immune response to HIV-1 gag cytotoxic T lymphocyte or to HIV-1 gag T helper epitopes.

### Claim 31 (depends on 29)

The method of claim 29, wherein said HIV antigen is HIV-gag, pol, env, protease, rev, tat, nef, vif, or vpr.

### Claim 32 (depends on 29)

The method of claim 29, wherein said malaria antigen is circumsprozoite protein (CSP), sporozoite surface protein 2 (PfSSP), liver stage antigen 1 (LSA1), merozoite surface protein 1 (MSP-1), serine repeat antigen and AMA-1, Pfs25, schizont export protein, 19 repeats of the sprozoite surface protein (NANP), SPf66, recombinant (Asn-Ala-Pro15Asn-Val-Asp-Pro)2-Leu-Arg(R32LR) protein covalently bound to a purified Pseudomonas aeruginosa toxin, NYVAC-Pf7, (NANP)19-5.1, (RTS,S, RTS,S/AS01), or a combination thereof.

### Claim 33 (depends on 29)

The method of claim 29, wherein said tuberculosis antigen is ESAT-6, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64, MPT64, Ag85A, Ag85B (MPT59), Mtb39, MPB59, Ag85C, 19 kDa lipoprotein, MPT32 and alpha-crystallin, EsxG, Rv2430c, Rv2041c, or at least on T-cell epitope of any of the above.

### Claim 34 (depends on 22)

The method of claim 22, further comprising the step of administering a booster vaccination.

### Claim 35 (depends on 34)

The method of claim 34, wherein said booster vaccination comprises a DNA vaccine encoding said antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, a recombinant polypeptide comprising said antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, a viral vector encoding said antigen fused to an additional immunogenic polypeptide or a signal sequence thereof or a live recombinant Listeria vaccine vector.

### Claim 36 (depends on 22)

The method of claim 22, wherein said Th1 immune response is a cytotoxic T-cell response or a memory T-cell response.

### Claim 37 (depends on 22)

The method of claim 22, wherein said Listeria vaccine vector is a recombinant auxotrophic dal/dat mutant Listeria strain.

### Claim 38 (depends on 22)

The method of claim 22, wherein said Listeria vaccine vector comprises an actA gene mutation.

### Claim 39 (depends on 22)

The method of claim 22, wherein said Listeria vaccine vector comprises an inlB gene mutation.

### Claim 40 (depends on 22)

The method of claim 22, wherein said Listeria vaccine vector comprises an actA and inlB gene mutation.

### Claim 41 (depends on 22)

The method of claim 22, wherein said immune response is against an infectious disease in said subject.

### Claim 42 (depends on 22)

The method of claim 22, wherein said infectious disease is amebiasis, an HIV infection, a malaria infection, a leishmania infection, a trichuris infection, or a tuberculosis infection.
